vs
Side-by-side financial comparison of Cronos Group Inc. (CRON) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($213.7M vs $44.5M, roughly 4.8× Cronos Group Inc.). USANA HEALTH SCIENCES INC runs the higher net margin — -3.1% vs -4.1%, a 1.0% gap on every dollar of revenue. On growth, Cronos Group Inc. posted the faster year-over-year revenue change (47.0% vs 6.7%). Cronos Group Inc. produced more free cash flow last quarter ($9.7M vs $-5.2M). Over the past eight quarters, Cronos Group Inc.'s revenue compounded faster (32.7% CAGR vs -1.7%).
Cronos Group Inc. is a global cannabinoid firm specializing in cultivation, processing, and distribution of cannabis-derived products including wellness supplements, consumer goods, and medical cannabis. It serves North America, Europe, and Asia Pacific, catering to regulated recreational and medical consumer segments with quality-controlled offerings.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
CRON vs USNA — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $44.5M | $213.7M |
| Net Profit | $-1.8M | $-6.5M |
| Gross Margin | 36.4% | 77.2% |
| Operating Margin | -16.8% | 0.6% |
| Net Margin | -4.1% | -3.1% |
| Revenue YoY | 47.0% | 6.7% |
| Net Profit YoY | -104.2% | -161.5% |
| EPS (diluted) | $-0.01 | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.5M | — | ||
| Q3 25 | $36.3M | $213.7M | ||
| Q2 25 | $33.5M | $235.8M | ||
| Q1 25 | $32.3M | $249.5M | ||
| Q4 24 | $30.3M | $213.6M | ||
| Q3 24 | $34.3M | $200.2M | ||
| Q2 24 | $27.8M | $212.9M | ||
| Q1 24 | $25.3M | $227.8M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $26.0M | $-6.5M | ||
| Q2 25 | $-39.7M | $9.7M | ||
| Q1 25 | $6.1M | $9.4M | ||
| Q4 24 | $43.7M | $4.5M | ||
| Q3 24 | $8.3M | $10.6M | ||
| Q2 24 | $-8.8M | $10.4M | ||
| Q1 24 | $-2.2M | $16.5M |
| Q4 25 | 36.4% | — | ||
| Q3 25 | 50.4% | 77.2% | ||
| Q2 25 | 43.4% | 78.7% | ||
| Q1 25 | 42.6% | 79.0% | ||
| Q4 24 | 35.7% | 82.0% | ||
| Q3 24 | 10.5% | 80.4% | ||
| Q2 24 | 22.7% | 81.1% | ||
| Q1 24 | 17.7% | 81.1% |
| Q4 25 | -16.8% | — | ||
| Q3 25 | -1.4% | 0.6% | ||
| Q2 25 | -15.9% | 7.1% | ||
| Q1 25 | -12.6% | 6.3% | ||
| Q4 24 | -37.5% | 3.8% | ||
| Q3 24 | -98.2% | 7.8% | ||
| Q2 24 | -56.1% | 8.4% | ||
| Q1 24 | -63.1% | 10.8% |
| Q4 25 | -4.1% | — | ||
| Q3 25 | 71.4% | -3.1% | ||
| Q2 25 | -118.7% | 4.1% | ||
| Q1 25 | 19.0% | 3.8% | ||
| Q4 24 | 144.3% | 2.1% | ||
| Q3 24 | 24.4% | 5.3% | ||
| Q2 24 | -31.5% | 4.9% | ||
| Q1 24 | -8.9% | 7.3% |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.07 | $-0.36 | ||
| Q2 25 | $-0.10 | $0.52 | ||
| Q1 25 | $0.02 | $0.49 | ||
| Q4 24 | $0.12 | $0.23 | ||
| Q3 24 | $0.02 | $0.56 | ||
| Q2 24 | $-0.02 | $0.54 | ||
| Q1 24 | $-0.01 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $831.8M | $145.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $528.1M |
| Total Assets | $1.2B | $726.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $831.8M | — | ||
| Q3 25 | $824.2M | $145.3M | ||
| Q2 25 | $834.4M | $151.3M | ||
| Q1 25 | $837.8M | $179.6M | ||
| Q4 24 | $858.8M | $181.8M | ||
| Q3 24 | $862.0M | $364.9M | ||
| Q2 24 | $848.2M | $332.4M | ||
| Q1 24 | $855.1M | $328.3M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $528.1M | ||
| Q2 25 | $1.1B | $531.1M | ||
| Q1 25 | $1.1B | $529.8M | ||
| Q4 24 | $1.1B | $532.1M | ||
| Q3 24 | $1.1B | $533.1M | ||
| Q2 24 | $1.1B | $512.2M | ||
| Q1 24 | $1.1B | $500.0M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $726.6M | ||
| Q2 25 | $1.2B | $734.5M | ||
| Q1 25 | $1.2B | $746.6M | ||
| Q4 24 | $1.2B | $748.2M | ||
| Q3 24 | $1.2B | $671.3M | ||
| Q2 24 | $1.1B | $631.4M | ||
| Q1 24 | $1.1B | $629.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $-2.0M |
| Free Cash FlowOCF − Capex | $9.7M | $-5.2M |
| FCF MarginFCF / Revenue | 21.8% | -2.4% |
| Capex IntensityCapex / Revenue | 4.8% | 1.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $149.0K | $18.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.8M | — | ||
| Q3 25 | $13.3M | $-2.0M | ||
| Q2 25 | $2.8M | $12.2M | ||
| Q1 25 | $-2.1M | $15.5M | ||
| Q4 24 | $7.7M | $5.8M | ||
| Q3 24 | $11.6M | $29.5M | ||
| Q2 24 | $1.7M | $8.0M | ||
| Q1 24 | $-2.2M | $17.7M |
| Q4 25 | $9.7M | — | ||
| Q3 25 | $8.8M | $-5.2M | ||
| Q2 25 | $-1.0M | $7.2M | ||
| Q1 25 | $-17.4M | $12.7M | ||
| Q4 24 | $4.2M | $4.0M | ||
| Q3 24 | $5.2M | $27.1M | ||
| Q2 24 | $1.0M | $5.3M | ||
| Q1 24 | $-3.9M | $14.5M |
| Q4 25 | 21.8% | — | ||
| Q3 25 | 24.3% | -2.4% | ||
| Q2 25 | -3.0% | 3.0% | ||
| Q1 25 | -53.8% | 5.1% | ||
| Q4 24 | 13.8% | 1.9% | ||
| Q3 24 | 15.1% | 13.6% | ||
| Q2 24 | 3.7% | 2.5% | ||
| Q1 24 | -15.5% | 6.4% |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 12.3% | 1.5% | ||
| Q2 25 | 11.5% | 2.1% | ||
| Q1 25 | 47.3% | 1.1% | ||
| Q4 24 | 11.7% | 0.8% | ||
| Q3 24 | 18.7% | 1.2% | ||
| Q2 24 | 2.6% | 1.3% | ||
| Q1 24 | 6.8% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | -0.34× | 1.65× | ||
| Q4 24 | 0.18× | 1.29× | ||
| Q3 24 | 1.39× | 2.78× | ||
| Q2 24 | — | 0.77× | ||
| Q1 24 | — | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRON
| Cannabis Flower | $33.7M | 76% |
| Cannabis Extracts | $10.8M | 24% |
USNA
| Direct Selling | $175.8M | 82% |
| Hiya | $30.8M | 14% |
| All Other | $7.0M | 3% |
